Top Markets
Coin of the day
Addex Therapeutics Ltd Addex Therapeutics Ltd

Addex Therapeutics Ltd

ADXN
Rang in Aktien #33378
Addex Therapeutics Ltd, a biopharmaceutical company in its development phase,... Addex Therapeutics Ltd, a biopharmaceutical company in its development phase, specializes in the discovery, progression, and commercialization of small-molecule pharmaceutical products designed to address central nervous system (CNS) conditions. Based in Geneva, Switzerland, the firm's core research centers on identifying oral small molecule allosteric modulators that interact with G-protein coupled receptors. Its leading clinical programs feature Dipraglurant, intended for the treatment of levodopa-induced dyskinesia in Parkinson's disease and dystonia; ADX71149, targeting epilepsy and various other neurological disorders; and GABAB PAM, developed to combat addiction. Addex has established strategic licensing and collaborative partnerships with organizations including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002, the company changed its name from Addex Pharmaceuticals Ltd to its current designation in March 2012.
Aktienkurs
$0.05124204
Marktkapitalisierung
$7.78M
Veränderung (1 Tag)
0.51%
Veränderung (1 Jahr)
-23.73%
Land
CH
Handel Addex Therapeutics Ltd (ADXN)

Kategorie

P/S-Verhältnis für Addex Therapeutics Ltd (ADXN)
P/S-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Addex Therapeutics Ltd beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/S-Verhältnis bei 0.
P/S-Verlauf für Addex Therapeutics Ltd von 2026 bis 2026
P/S-Verhältnis zum Jahresende
Jahr P/S-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/S-Verhältnis P/S-Verhältnis-Differenz Land
10.17 -
US
10.13 -
NL
- -
CH
- -
KR
4.74 -
BE